See which technologies are shaping the next generation of liquid biopsy at ISLB 2026. The technical session “Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches” will spotlight innovative methods expanding what can be detected, characterised and understood through liquid biopsy. Topics will include: • Extracellular vesicles as functional biomarkers • Microfluidic isolation and functional analysis of circulating tumour cells • Multimodal liquid biopsy in small cell lung cancer • Diagnostic leukapheresis and molecular characterisation of CTCs • Multi-omic approaches to blood-based cancer biomarkers Chaired by Dr María José Serrano and Prof Paola Gazzaniga, the session will feature contributions from: • Dr Kenneth Witwer • Assoc. Prof. Han Wei Hou • Dr Alfonso Calvo • Prof Nikolas Stoecklein • Prof Megan Hitchins • Dr Mattia Boeri Join us in Madrid on Saturday, 7 November, as researchers explore the technologies and emerging approaches helping define the future of liquid biopsy. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info #ISLB2026 #LiquidBiopsy #CTCs #ExtracellularVesicles #CancerResearch #PrecisionOncology

Advancing liquid biopsy requires more than promising technology — it requires collaboration, robust evidence and meaningful exchange between research and clinical practice. Researchers, clinicians and industry experts will come together in Madrid to examine the latest evidence, share perspectives and explore how liquid biopsy can continue to support more informed approaches to cancer care. Be part of the discussions shaping the next chapter of liquid biopsy. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info #ISLB2026 #LiquidBiopsy #PrecisionOncology #CancerResearch #Oncology #CancerCare

🧬 ISLB Global Molecular Tumor Board: Breast Cancer Thank you to everyone who joined today’s ISLB Global Molecular Tumor Board – Breast Cancer, part of the ISLB Education Series. The interactive session explored the evolving role of liquid biopsy and ctDNA in breast cancer, with a particular focus on molecular residual disease (MRD) in early triple-negative breast cancer, ctDNA dynamics around neoadjuvant therapy and surgery, and the potential future role of molecular monitoring in treatment escalation and de-escalation. A key discussion centered on an increasingly important question: Can ctDNA move from predicting recurrence to actually guiding treatment decisions in early breast cancer? Many thanks to our moderators Mark Basik and Adriana Aguilar, presenter Mark Basik, and invited panelists Cristiano Ferrario, @AlexandrePCheng , @jvburnier , and Parvaneh Fallah for an engaging and clinically relevant discussion. On behalf of the ISLB Education Committee, coordinated by @BrunaPellini and @JordiRemon , thank you to our faculty and participants for making this another highly interactive Global MTB session. 🌍 Advancing molecular diagnostics through global discussion, education, and collaboration. #ISLB #LiquidBiopsy #BreastCancer #ctDNA #MRD #TNBC #PrecisionOncology #MolecularTumorBoard @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @BenBleibergMD @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD @DrYukselUrun

🌍 New @TheLancetOncol Commission: Making Precision Oncology More Equitable Precision oncology is advancing rapidly but access to cancer genomics remains deeply unequal worldwide. The new Lancet Oncology Commission reports that: 🧬 7–8 million patients with cancer require molecular testing each year 🌍 Millions still lack access to guideline-indicated biomarker testing 📊 Only 2% of biomarker-based trial–country activity analysed occurred in LMICs 🩸 Liquid biopsy is increasingly integrated into molecular profiling, MRD monitoring and resistance assessment The message is clear: innovation alone is not enough. Precision oncology must be implemented with evidence, quality, affordability, workforce capacity, reimbursement and equitable access at its core. For the liquid biopsy community, this means moving beyond “Can we detect it?” toward: “Can every eligible patient access testing, interpretation and an effective treatment?” @DrYukselUrun @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD #PrecisionOncology #CancerGenomics #LiquidBiopsy #ctDNA #GlobalOncology #HealthEquity #CancerResearch #ISLB

⏳ The deadline is approaching! There is still time to submit your application for the 2026 ISLB Grants. The International Society of Liquid Biopsy (ISLB) is awarding a total of $50,000 USD across two incredible funding opportunities to accelerate advancements in non-invasive diagnostics. Are you an early-career scientist or part of an innovative research team? We want to hear from you! 🔬 The Rabab Gaafar Young Investigator Grant: $25,000 USD to support early-career scientists in their postdoctoral stage. 💡 The Garcia-Puche Grant for Innovation: $25,000 USD to support researchers and entrepreneurs developing technologies for faster, more accurate diagnostics. 🗓️ Submit your proposal by September 20, 2026. Secure funding for your ongoing research today. Find full details and application portals below: 🔗 Rabab Gaafar Grant: islb.info/islb-investigator-…🔗 Garcia-Puche Grant: islb.info/islb-innovation-gr… #LiquidBiopsy #ResearchGrants #MedicalInnovation #ISLB #CallForProposals #OncologyFunding #FutureOfMedicine @drgandara @ChristianRolfo @UmbertoMalapel1 @ElJanLe

Find out what awaits at the 8th Annual Congress of Liquid Biopsy in Madrid. Across three days of scientific exchange, ISLB 2026 will bring together the liquid biopsy community to explore the latest research, emerging technologies and clinical applications shaping the field. Programme activities will include (but not limited to): 🔹 Expert-led workshops & sessions exploring evolving methodologies and clinical applications 🔹 Oral abstract sessions showcasing important new research and findings 🔹 Dedicated poster sessions and a guided poster tour designed to encourage discussion, feedback and collaboration These activities form part of a broader programme covering circulating tumour cells, tumour-derived vesicles, RNA, proteomics, tumour-specific research, industry-supported sessions and much more. Join researchers, clinicians and industry experts in Madrid for meaningful scientific exchange and new opportunities to connect. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 → islb-congress.info #ISLB2026 #LiquidBiopsy #CancerResearch #PrecisionOncology #ClinicalResearch #ScientificCongress #Madrid

🏆 Congratulations to Dr. Natasha Leighl, recipient of the ISLB 2026 Gandara Clinical Research Award. Dr. Leighl is Division Head of Medical Oncology and Hematology at Princess Margaret Cancer Centre and the UHN-Sinai Health Department of Medicine, Daniel E. Bergsagel Chair in Medical Oncology, and Professor at the University of Toronto. An internationally recognized leader in lung cancer precision medicine, diagnostics, clinical management, and drug development, Dr. Leighl has made transformative contributions to advancing patient care worldwide. Her pioneering work in international clinical trials, new drug development, and the implementation of liquid biopsy in clinical practice has helped shape the future of lung cancer diagnosis and treatment. With more than 450 peer-reviewed publications and recognition as a Clarivate Highly Cited Researcher and ScholarGPS Highly Ranked Scholar, Dr. Leighl continues to drive innovation while mentoring the next generation of oncology leaders. In addition to her research achievements, Dr. Leighl serves on the Board of Directors of the International Association for the Study of Lung Cancer (IASLC), chairs multiple international guideline initiatives, leads the ISLB Education Committee, and serves as ISLB Secretary-Elect. We are honoured to recognize Dr. Leighl's exceptional contributions to clinical research, education, and patient care with the ISLB 2026 Gandara Clinical Research Award. 𝗟𝗲𝗮𝗿𝗻 𝗠𝗼𝗿𝗲 → islb-congress.info Please join us in congratulating Dr. Leighl on this well-deserved recognition. #ISLB2026 #GandaraClinicalResearchAward #LungCancer #ClinicalResearch #PrecisionMedicine #LiquidBiopsy #Oncology #CancerResearch

The ISLB 2026 speaker lineup is now live. Meet the innovators and rising leaders shaping this year's scientific program, each contributing a unique perspective with exceptional insights and bold ideas at the congress. These speakers represent a globally recognized group of leaders in liquid biopsy, precision oncology, molecular diagnostics, translational cancer research, and emerging biomarker technologies. Collectively, they include medical oncologists, pathologists, biostatisticians, surgeon-scientists, molecular biologists, geneticists, public health leaders, and biomedical engineers from leading institutions across North America, Europe, Asia, and Australia. Making ISLB 2026 a congress led by many of the world's foremost experts shaping the future of cancer diagnostics and personalized medicine in Liquid Biopsy. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗹𝗶𝘀𝘁 → lnkd.in/gyWKjE9T #ISLB2026 #LiquidBiopsy #CancerResearch #PrecisionMedicine #Medicine #Cancer #Research #Science #Oncology #MolecularDiagnostics #Pathologists